Suven Life Sciences logo

Suven Life Sciences

SUVEN NSE

Key Fundamentals

MicrocapHealthcare TechnologyHealthcare
Market Cap
₹9,989 Cr
Volatility
Moderate
P/E Ratio
-29
EBITDA
₹-271 Cr
Return on Equity
-46.73%
Debt to Equity
0.03
Book Value
₹24.23
52W High
₹403.35
52W Low
₹124.11

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Strengths

1
  • Company is almost debt free.

Weaknesses

7
  • Stock is trading at 15.9 times its book value
  • Company has low interest coverage ratio.
  • Promoter holding has decreased over last quarter: -4.68%
  • The company has delivered a poor sales growth of -12.0% over past five years.
  • Company has a low return on equity of -65.9% over last 3 years.
  • Debtor days have increased from 63.7 to 77.5 days.
  • Working capital days have increased from 55.6 days to 506 days

Growth Rate

Revenue Growth
19.32% higher than 3Y
Net Income Growth
71.94% lower than 3Y
Cash Flow Change
-93.1% higher than 3Y
ROE
-68.03% higher than 3Y
ROCE
-68.29% lower than 3Y
EBITDA Margin (Avg.)
45.71% lower than 3Y

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 69d ago
AI opinion · based on fundamentals
Risk high

Suven Life Sciences trades at a market cap of ₹8,475 Cr with a negative PE of -31.3x and negative ROE of -79% in the last year, reflecting ongoing losses despite being nearly debt-free. The stock has appreciated 28% over the past year even as sales declined 12% over five years, indicating a sharp disconnect between market pricing and operating fundamentals.

Bull Case 7
  • Company is almost debt-free, providing financial flexibility and low insolvency risk in a capital-intensive healthcare sector
  • Promoter holding increased by 2.79% over the last quarter, signaling insider confidence in the business outlook
  • Stock CAGR of 73% over 3 years suggests sustained market interest and positive sentiment around the company's pipeline potential
  • TTM sales growth has turned positive at 7%, potentially indicating a reversal from the negative 19% 3-year compounded sales decline
  • 10-year stock CAGR of 38% demonstrates long-term wealth creation for shareholders despite operational challenges
  • Near-zero debt gives the company runway to invest in R&D and drug development without servicing obligations eating into cash flows
  • 1-year stock return of 28% outperforms broader market indices, reflecting market re-rating of the business
Bear Case 8
  • Negative PE of -31.3x confirms the company is loss-making at the net income level, with compounded profit declining 67% on a TTM basis
  • 3-year ROE of -65% and last year ROE of -79% indicate severe and worsening destruction of shareholder equity
  • Stock trades at 14.6x book value despite negative returns on equity, suggesting extreme valuation premium relative to asset base
  • Compounded sales growth is negative at -12% over 5 years and -35% over 10 years, reflecting a structurally shrinking revenue base
  • Working capital days have ballooned from 2,939 to 9,156 days, indicating severely inefficient capital utilization and potential cash conversion issues
  • Debtor days increased from 63.7 to 77.5 days, suggesting deterioration in collection efficiency and potential customer concentration risk
  • Zero dividend yield means shareholders receive no income return while bearing significant operational risk from ongoing losses
  • Low interest coverage ratio despite being nearly debt-free suggests operating earnings are insufficient to cover even minimal financial obligations

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 69d ago
Positives 4
  • Ropanicant Phase-2b hits primary endpoint Jun 17

    Phase-2b trial for Major Depressive Disorder showed statistically significant improvement on primary endpoint with no serious safety signals. Company plans to initiate global Phase-3 studies.

  • SUVN-I6107 advances to Phase-2 Jun 16

    Phase-1 completed successfully showing favorable safety and CNS activity. Drug now moves into Phase-2 clinical development.

  • Samelisant data at SLEEP-2026 Jun 12

    Three posters to be presented at SLEEP-2026 in Baltimore, including Phase-2 results and Phase-3 study design for Samelisant.

  • 62 partnering meetings at BIO 2026 Jun 22

    Suven is showcasing its CNS portfolio at BIO International Convention in San Diego (Jun 22-25) with 62 scheduled partnering meetings for out-licensing and co-development.

Neutral 1
  • Promoters hold unpledged shares in FY26 Jun 17

    No promoter shares were pledged during FY26 as disclosed under SEBI regulations, indicating clean promoter holding structure.

TL;DR: Suven Life Sciences is firing on multiple cylinders in its clinical pipeline with positive Phase-2b data for Ropanicant in depression, Phase-2 advancement of SUVN-I6107, and upcoming Samelisant presentations. No headwinds are visible in recent news flow. The key risk remains typical biotech execution risk around Phase-3 trial outcomes and partnering timelines, but the near-term trend is clearly positive with pipeline catalysts stacking up through 2026.

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
4
3
2
2
1
3
2
1
2
1
3
2
4
Expenses
32
27
49
33
32
55
41
45
53
81
106
52
136
Operating Profit
-28
-24
-46
-30
-31
-52
-39
-44
-51
-80
-103
-51
-132
OPM %
-737%
-768%
-1885%
-1267%
-3024%
-2032%
-2435%
-2981%
-2714%
-8671%
-3678%
-3331%
-3711%
Other Income
6
13
6
4
4
4
2
1
1
4
3
7
8
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
2
2
2
2
1
1
2
1
1
1
1
2
2
PBT
-24
-13
-42
-28
-28
-50
-39
-44
-52
-77
-102
-46
-128
Tax %
0%
0%
0%
-4%
0%
0%
0%
0%
0%
0%
0%
0%
0%
Net Profit
-24
-13
-42
-27
-28
-50
-39
-44
-52
-77
-102
-46
-128
EPS in Rs
-1.1
-0.58
-1.91
-1.22
-1.29
-2.28
-1.79
-2.01
-2.36
-3.4
-4.48
-1.73
-4.83
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
521
499
543
625
286
13
13
12
14
12
7
7
9
Expenses
361
398
414
427
300
128
93
134
139
140
172
291
375
Operating Profit
159
102
129
198
-14
-116
-80
-122
-126
-128
-166
-284
-366
OPM %
31%
20%
24%
32%
-5%
-917%
-593%
-1032%
-929%
-1094%
-2487%
-3999%
-4152%
Other Income
9
19
21
23
27
14
8
5
14
29
11
14
21
Interest
5
6
6
5
2
1
1
1
0
0
0
0
1
Depreciation
12
18
21
21
11
4
4
4
7
6
6
6
6
PBT
152
98
123
196
0
-106
-77
-122
-118
-106
-161
-276
-352
Tax %
28%
26%
29%
37%
15038%
-11%
-7%
0%
0%
-1%
0%
0%
—
Net Profit
109
72
87
124
-24
-94
-72
-122
-118
-105
-161
-276
-352
EPS in Rs
5.7
3.76
4.57
6.48
-1.25
-4.94
-3.78
-5.59
-5.42
-4.82
-7.37
-10.48
-14.44
Div. Payout %
7%
35%
15%
15%
-80%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
13
13
13
13
13
13
13
15
22
22
22
26
Reserves
547
583
654
755
226
131
95
82
354
248
88
565
Borrowings
109
83
71
34
3
6
5
3
2
1
0
17
Other Liabilities
105
74
78
118
62
33
16
9
12
14
25
16
Total Liabilities
773
751
816
919
303
182
128
108
389
285
135
624
Fixed Assets
172
305
306
308
22
25
21
38
37
28
60
73
CWIP
107
7
10
25
0
0
5
4
0
0
0
4
Investments
0
0
301
279
223
0
0
45
46
76
22
181
Other Assets
494
439
199
308
58
157
103
22
305
181
53
367
Total Assets
773
751
816
919
303
182
128
108
389
285
135
624
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
143
68
109
70
-53
-135
-96
-128
-116
-115
-155
-300
Investing
-110
-39
-311
-1
30
146
56
-22
-248
94
155
-462
Financing
179
-68
-30
-52
5
3
35
146
396
-1
-1
757
Net Cash Flow
212
-39
-232
17
-18
14
-5
-4
32
-22
-1
-5
Free Cash Flow
25
10
79
28
-92
-137
-102
-147
-119
-113
-193
-305
CFO/OP
113
93
111
57
262
114
119
104
91
95
93
106
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
28
39
31
36
3
66
48
40
22
40
73
78
Inventory Days
165
183
222
329
0
—
—
—
—
—
—
—
Days Payable
89
78
91
134
—
—
—
—
—
—
—
—
Cash Conversion Cycle
105
144
162
231
3
66
48
40
22
40
73
78
Working Capital Days
49
55
42
82
23
704
1,084
234
265
101
-440
506
ROCE %
—
13%
15%
24%
-4%
-54%
-58%
-118%
-53%
-36%
-87%
-80%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Suven Life Sciences insights

36 extracted metrics + investor summaries across FY14–FY26.

Log in — free

Shareholding Pattern

FIIs0.57%Promot.70.08%DIIs2.93%Others5.06%Public21.37%As ofJun 2026

Documents

Frequently Asked Questions about Suven Life Sciences

What does Suven Life Sciences Ltd do?
Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.[1] [2]
Where is Suven Life Sciences Ltd (SUVEN) listed?
Suven Life Sciences Ltd trades as SUVEN on the NSE and under code 530239 on the BSE.
Which sector does Suven Life Sciences Ltd belong to?
Suven Life Sciences Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Suven Life Sciences Ltd?
Suven Life Sciences Ltd has a market capitalisation of ₹9,989 Cr, which places it in the Mid Cap band.
What is the PE ratio of Suven Life Sciences Ltd?
Suven Life Sciences Ltd trades at a PE ratio of -29.00, against a book value of ₹24.23 per share.
What is the 52-week high and low of Suven Life Sciences Ltd?
Over the last 52 weeks Suven Life Sciences Ltd has traded between ₹124.11 and ₹403.35.
What is the Return on Equity (ROE) of Suven Life Sciences Ltd?
Suven Life Sciences Ltd reported a return on equity of -46.73%. Its debt-to-equity ratio is 0.03.

Company Information

Suven Life Sciences is a clinical-stage biopharmaceutical company developing proprietary New Chemical Entities for central nervous system disorders. Its five clinical assets target agitation in Alzheimer’s dementia, narcolepsy, major depressive disorder and cognitive disorders.[1] [2]

Website suven.com
CEO Mr. Venkateswarlu Jasti M.Pharm. M.S.
Employees 138
Listed 2003-10-23
Face Value ₹ 1
Issued Size 22,74,74,207

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/SUVEN.md for Suven Life Sciences Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List